National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2016 (No. 1) (PB 24 of 2016)

Overview

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2016 (No. 1) was enacted to amend the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010, responding to the introduction of new pricing regulations under section 99ADH of the National Health Act 1953. This amendment, made by the Minister for Health, removes specific drugs from their designated therapeutic groups as these drugs will be subject to new price disclosure requirements as of 1 April 2016. This legislative action ensures that the therapeutic groups are updated to reflect the current status of these drugs, in line with the Act's provision for dynamic management of pharmaceutical benefits. The determination also removes the entire therapeutic groups once the last drugs within them are affected by the new regulations. This amendment is effective from 1 April 2016 and is compatible with human rights as it supports the progressive realisation of the right to health by ensuring that access to essential medicines remains evidence-based and affordable.

Scope and Application

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2016 (No. 1) amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010, which sets out various therapeutic groups and the listed drugs within those groups under the National Health Act 1953. This amending instrument applies to listed drugs and their therapeutic groupings within the Pharmaceutical Benefits Scheme (PBS), removing specific drugs from their respective therapeutic groups. It affects entities and individuals involved in the prescription, provision, and regulation of pharmaceutical benefits in Australia, particularly in relation to the pricing and disclosure of drug prices under section 99ADH of the Act. The amendment applies nationally, impacting the classification and administration of drugs across all states and territories. There are no stated exclusions or exemptions in this particular amendment; however, the determination's application can be extended or restricted through subordinate instruments made under the authority of the Act. This legislative instrument is compatible with human rights, facilitating the enjoyment of the highest attainable standard of physical and mental health through the PBS, as it ensures that decisions about drug subsidies are evidence-based.

Key Provisions

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2016 (No. 1) (the Determination) is a legislative instrument made under subsection 84AG(1) of the National Health Act 1953 (the Act). This Determination amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (the Principal Determination), which sets out the therapeutic groups and the listed drugs that fall within those groups (section 1). The primary changes introduced by this Amendment concern the removal of specific drugs from their respective therapeutic groups, effective from 1 April 2016. Specifically, the listed drug 'Esomeprazole' is removed from the PPI group, and 'Desvenlafaxine' is removed from the Venlafaxine group (section 2). Consequently, these therapeutic groups are also removed as they no longer contain any listed drugs (section 2). The determination relies on subsection 33(3) of the Acts Interpretation Act 1901 to revoke or vary the Principal Determination where there is no express power cited in this instrument. The Determination imposes certain obligations on the parties and entities governed by the Act. It mandates that the listed drugs, Esomeprazole and Desvenlafaxine, are no longer considered part of the PPI and Venlafaxine groups, respectively, for the purposes of the Pharmaceutical Benefits Scheme (PBS). These changes reflect the application of section 99ADH, which deals with price disclosure and price reductions (section 3). The Pharmaceutical Benefits Advisory Committee (PBAC) and other relevant entities must ensure compliance with these amendments in their operations and decision-making processes regarding the PBS. Failure to comply with the provisions of the Determination may result in legal consequences. While the Determination itself does not explicitly outline offences or penalties for non-compliance, the overarching National Health Act 1953 provides a framework for enforcement. Penalties for breaches of the Act can include fines and, in more severe cases, imprisonment. The specific penalties are determined based on the nature and severity of the breach, as outlined in the Act and relevant subsidiary legislation. Non-compliance with the therapeutic group classifications could potentially impact the eligibility for pharmaceutical benefits and the administration of the PBS, leading to broader regulatory and legal repercussions for affected parties.